About Affymetrix (NASDAQ:AFFX)
Affymetrix, Inc. (Affymetrix) is a provider of life science products and molecular diagnostic products that enable parallel analysis of biological systems at the gene, protein and cell level. The Company operates through two business segments: Affymetrix Core and eBioscience. The Affymetrix Core segment focuses on the development, manufacture and commercialization of systems for genetic analysis in the life sciences, agricultural biotechnology (AgBio) and diagnostic industry. The eBioscience segment primarily focuses on the development, manufacture, marketing and distribution of research products in the areas of flow cytometry, immunoassays, microscopic imaging and other protein-based analyses. The Company sells its products to genomic research centers, academic institutions, government and private laboratories, as well as pharmaceutical, diagnostic and biotechnology companies. It maintains sales and distribution operations across the United States, Europe, Latin America and Asia.
Industry, Sector and Symbol:
- Industry: Bio Diagnostics & Testing
- Sub-Industry: Life Sciences Tools & Services
- Sector: N/A
- Symbol: NASDAQ:AFFX
- CUSIP: 00826T10
- Web: www.affymetrix.com
- Trailing EPS: $0.12
- Net Margins: 4.24%
- Return on Equity: 4.84%
- Return on Assets: 2.97%
- Outstanding Shares: 80,490,000
Frequently Asked Questions for Affymetrix (NASDAQ:AFFX)
What is Affymetrix's stock symbol?
Affymetrix trades on the NASDAQ under the ticker symbol "AFFX."
How were Affymetrix's earnings last quarter?
Affymetrix, Inc. (NASDAQ:AFFX) announced its quarterly earnings data on Wednesday, February, 17th. The scientific and technical instruments company reported $0.09 EPS for the quarter, missing the consensus estimate of $0.11 by $0.02. The scientific and technical instruments company had revenue of $95.60 million for the quarter, compared to the consensus estimate of $93.29 million. Affymetrix had a net margin of 4.24% and a return on equity of 4.84%. During the same quarter last year, the company posted $0.09 earnings per share. View Affymetrix's Earnings History.
Who are some of Affymetrix's key competitors?
Some companies that are related to Affymetrix include Universal Forest Products (UFPI), Loxo Oncology (LOXO), Children's Place, Inc. (The) (PLCE), Eldorado Resorts (ERI), Horizon Pharma PLC (HZNP), Cal-Maine Foods (CALM), Qualys (QLYS), Allegiant Travel Company (ALGT), Viper Energy Partners LP (VNOM), Ocean Rig UDW (ORIG), National General Holdings Corp (NGHC), Trustmark Corporation (TRMK), The Advisory Board Company (ABCO), Finisar Corporation (FNSR), Amicus Therapeutics (FOLD), Potlatch Corporation (PCH), Pattern Energy Group (PEGI) and HSN (HSNI).
How do I buy Affymetrix stock?
Shares of Affymetrix can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Affymetrix's stock price today?
One share of Affymetrix stock can currently be purchased for approximately $14.01.
How big of a company is Affymetrix?
Affymetrix has a market capitalization of $1.13 billion.
How can I contact Affymetrix?
Affymetrix's mailing address is 3420 Central Expy, SANTA CLARA, CA 95051-0703, United States. The scientific and technical instruments company can be reached via phone at +1-408-7315000.
MarketBeat Community Rating for Affymetrix (NASDAQ AFFX)MarketBeat's community ratings are surveys of what our community members think about Affymetrix and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Analysts' Consensus Rating for Affymetrix (NASDAQ:AFFX) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||0 Sell Ratings, 0 Hold Ratings, 0 Buy Ratings, 0 Strong Buy RatingsNo ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Analysts' Consensus Price Target: ||N/A|
Consensus Price Target History for Affymetrix (NASDAQ:AFFX)
Analysts' Ratings History for Affymetrix (NASDAQ:AFFX)
(Data available from 11/20/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|4/3/2016||Cantor Fitzgerald||Reiterated Rating||Hold||$14.00||N/A|
|3/23/2016||BTIG Research||Reiterated Rating||Neutral||N/A|
|2/18/2016||Cowen and Company||Boost Price Target||Market Perform||$10.00 -> $14.00||N/A|
|1/11/2016||Mizuho||Downgrade||Buy -> Neutral||$14.00||N/A|
Earnings History and Estimates Chart for Affymetrix (NASDAQ:AFFX)
Earnings History by Quarter for Affymetrix (NASDAQ AFFX)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|2/17/2016||Q415||$0.11||$0.09||$93.29 million||$95.60 million||View||N/A|
|10/28/2015||Q315||$0.08||$0.10||$88.04 million||$86.50 million||View||Listen|
|7/29/2015||Q215||$0.07||$0.12||$88.61 million||$89.00 million||View||Listen|
|4/29/2015||Q115||$0.04||$0.10||$87.30 million||$88.70 million||View||Listen|
|2/4/2015||Q414||$0.07||$0.09||$91.80 million||$93.50 million||View||Listen|
|10/30/2014||Q314||$0.04||$0.08||$84.40 million||$87.10 million||View||Listen|
|7/31/2014||Q214||$0.03||$0.07||$83.30 million||$85.40 million||View||Listen|
|5/1/2014||Q114||$0.02||$0.03||$81.10 million||$83.00 million||View||Listen|
|2/5/2014||Q413||$0.07||$0.02||$89.98 million||$92.60 million||View||Listen|
|7/31/2013||Q2 2013||($0.01)||$0.04||$78.53 million||$79.46 million||View||Listen|
|4/30/2013||Q1 2013||($0.02)||($0.01)||$78.04 million||$77.90 million||View||Listen|
|1/31/2013||Q4 2012||($0.03)||($0.02)||$84.06 million||$84.40 million||View||Listen|
|11/5/2012||Q312||($0.03)||($0.03)||$84.56 million||$79.60 million||View||N/A|
Earnings Estimates for Affymetrix (NASDAQ:AFFX)
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Affymetrix (NASDAQ:AFFX)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Affymetrix (NASDAQ AFFX)
Insider Trades by Quarter for Affymetrix (NASDAQ AFFX)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|12/15/2015||Robert H Trice||Director||Sell||2,500||$9.40||$23,500.00|| |
|11/17/2015||Robert H Trice||Director||Sell||2,500||$9.00||$22,500.00|| |
|10/15/2015||Robert H Trice||Director||Sell||2,500||$9.00||$22,500.00|| |
|7/20/2015||Frank Witney||CEO||Sell||37,991||$11.20||$425,499.20|| |
|7/10/2015||Frank Witney||CEO||Sell||62,756||$11.00||$690,316.00|| |
|6/26/2015||Frank Witney||CEO||Sell||75,000||$11.22||$841,500.00|| |
|6/22/2015||David A Weber||EVP||Sell||33,879||$12.00||$406,548.00|| |
|6/19/2015||David A Weber||EVP||Sell||14,760||$12.00||$177,120.00|| |
|6/4/2015||Frank Witney||CEO||Sell||75,000||$11.78||$883,500.00|| |
|2/17/2015||Gavin Wood||CFO||Sell||1,300||$11.40||$14,820.00|| |
|1/20/2015||Gavin Wood||CFO||Sell||22,500||$11.77||$264,825.00|| |
|1/12/2015||Gavin Wood||CFO||Sell||10,200||$10.77||$109,854.00|| |
|12/29/2014||Gavin Wood||CFO||Sell||18,734||$10.20||$191,086.80|| |
|11/19/2013||Robert Trice||Director||Sell||6,205||$7.98||$49,515.90|| |
|8/21/2012||Timothy C Barabe||CFO||Buy||10,000||$3.75||$37,500.00|| |
|8/17/2012||Timothy C Barabe||CFO||Buy||5,550||$3.99||$22,144.50|| |
|8/13/2012||Timothy C Barabe||CFO||Buy||4,450||$3.99||$17,755.50|| |
Latest Headlines for Affymetrix (NASDAQ AFFX)
Affymetrix (NASDAQ AFFX) Chart for Monday, November, 20, 2017